Clinical Trial: Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT05774639) titled 'Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria' on Feb. 25.

Brief Summary: The purpose of the study is to compare the efficacy, safety, tolerability, and immunogenicity of ADL-018 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment

Study Type: Interventional

Condition: Chronic Idiopathic Urticaria

Intervention: * Drug: Omalizumab Injection

ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)

Other Name: ADL-018

* Drug: Xolair Pref...